Focus:
Central Nervous System
-
30 July 2019 projects
Eisai’s New Oral Solid Dose Production Facility, Suzhou
Eisai China has built a new oral solid dose (OSD) production facility at its new Suzhou plant in China.
-
22 July 2019 News
Biohaven’s Nurtec fails to obtain FDA approval for ALS
Biohaven Pharmaceutical has failed to receive the US Food and Drug Administration (FDA) approval for Nurtec (riluzole).
-
12 July 2019 News
Amgen and Novartis discontinue Alzheimer’s drug development programme
Amgen and Novartis have announced the discontinuation of their clinical development programme for CNP520 (umibecestat), a BACE1 inhibitor for Alzheimer’s disease, which the Arizona-based Banner Alzheimer’s Institute was also supporting.
-
12 July 2019 News
US researchers develop ‘EpiPen’ to treat injured spinal cords
Researchers at the University of Michigan in the US have developed a nanoparticles injection to prevent the immune system from overreacting to trauma in order to potentially prevent paralysis from...
-
12 July 2019 News
Eisai opens dementia-focused research facility in US
Japan-based Eisai has opened a US exploratory research facility in Cambridge, Massachusetts, to identify new drugs for the treatment of dementia.
-
11 July 2019 News
TBI-focused vasopharm closes a €9.5m financing round
German pharma company vasopharm has announced it has closed a €9.5m financing round, which was co-led by HeidelbergCapital Private Equity and EF Investments.
-
9 July 2019
Addex to lead mGlu7 NAM-focused PTSD consortium
Swiss-headquartered Addex Therapeutics has announced it will lead a consortium to develop small molecule negative allosteric modulators (NAMs) indicated to reduce fear memory in post-traumatic stress disorder (PTSD).
-
8 July 2019 Comment
Ground-breaking research finds inflammatory biomarkers in epileptogenesis
Research has found the presence of specific inflammatory proteins can be used as biomarkers for epilepsy and assist physicians with prognostic evaluations.
-
5 July 2019 Comment
Will gene therapy revolutionise the way we treat inheritable neuropathologies?
There are still challenges for the use of gene therapy in treating neuropathic diseases.
-
28 June 2019 News
FDA approves Alexion’s Soliris as first treatment for CNS disease NMOSD
Alexion Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has approved Soliris (eculizumab), a first-in-class complement inhibitor, for neuromyelitis optica spectrum disorder (NMOSD) patients who are anti-aquaporin-4...
Close
Close
Close
Go Top
